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Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that selectively affects 
optic nerves and spinal cord. It is considered a severe variant of multiple sclerosis (MS), and 
frequently is misdiagnosed as MS, but prognosis and optimal treatments differ. A serum 
immunoglobulin G autoantibody (NMO-IgG) serves as a specific marker for NMO. Here we 
show that NMO-IgG binds selectively to the aquaporin-4 water channel, a component of the 
dystroglycan protein complex located in astrocytic foot processes at the blood-brain barrier. 
NMO may represent the first example of a novel class of autoimmune channelopathy.
 
Inflammatory demyelinating diseases of the
central nervous system (CNS) are recognized
to be immune-mediated, but no disease-specific
microbial antigen or autoantigen has been
identified to date. Neuromyelitis optica (NMO;
formerly known as Devic’s disease) accounts
for approximately one third of the cases of
multiple sclerosis (MS) that are encountered in
Asia, where it is known as optic-spinal MS (1).
The characteristic immunopathology of NMO
is restricted to spinal cord and optic nerves,
and affects gray and white matter. IgG, IgM,
and products of complement activation are
deposited in a vasculocentric pattern, which
suggests a pathogenic role for autoantibody
(2). Blood vessels within demyelinating lesions
are distinctively thickened and hyalinized, dis-
proportionate to the patient’s age (3). Active
lesions exhibit swelling, infiltrating macrophages,
activated microglia, demyelination, axonal loss,
prominent necrosis, and variable perivascular in-
flammation, with evidence of eosinophils and
products of their exocytosis (2, 3). Chronic
lesions are characterized by gliosis, cystic degen-
eration, cavitation, and atrophy.
Typically, NMO has a worse outcome
than MS, with frequent and early relapses (4,
5). Vision and ambulation are impaired within
5 yr of its onset in 50% of patients, and 20%
succumb to respiratory failure from cervical
myelitis (5). Plasmapheresis has been reported
to improve the neurologic outcome for patients
who have NMO with severe longitudinally
extensive myelitis of recent onset (6). This ob-
servation further supports an autoantibody-
mediated pathogenesis for NMO. We recently
described an IgG specific for NMO in the serum
of 73% of patients who had NMO, and in 58%
of patients who had the Asian optic-spinal
form of MS. Patients who had classical (western)
MS—for which no biomarker is recognized—
were uniformly seronegative (7). Thus, sero-
positivity for NMO-IgG allows early diagnostic
distinction between patients who have NMO
and those who have MS. This distinction is
important prognostically and therapeutically
because optimal treatments differ for NMO
(immunosuppression; reference 8) and MS (im-
munomodulation with 
 

 
-IFN or glatiramer
acetate; reference 9). NMO-IgG binds to the
abluminal face of microvessels, pia, subpia, and
Virchow-Robin sheath in sections of normal
mouse CNS tissues. Its partial colocalization
with laminin (7) is consistent with the autoan-
tigen being a component of the glia limitans at
the blood–brain barrier (BBB; reference 10).
In this report we show that NMO-IgG binds
to the aquaporin-4 (AQP4) water channel.
 
RESULTS AND DISCUSSION
NMO antigen is in CNS and non-CNS tissues, 
and colocalizes with AQP4
 
To determine whether the NMO antigen is re-
stricted to the CNS, we tested NMO-IgG–
positive patients’ sera by indirect immunofluo-
rescence on sections of normal mouse liver,
kidney, and stomach tissues. In contrast to the
characteristic intense staining of pial and mi-
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crovascular elements in the brain, NMO-IgG did not bind to
any vascular or visceral autonomic neural elements in stom-
ach, kidney, or liver (e.g., myenteric and submucosal plexi,
or sympathetic nerves accompanying arterioles). However,
NMO-IgG bound prominently to distal urine-collecting tu-
bules in the renal medulla and to basolateral membranes of
epithelial cells deep in the gastric mucosa (Fig. 1 A); the im-
munoreactive gastric mucosal cells were identified immuno-
histochemically as parietal cells (not depicted). The distribu-
tion of NMO-immunoreactivity in CNS, kidney, and gastric
mucosa suggested the water channel protein, AQP4, as a can-
didate antigen (11). By use of dual immunostaining with
AQP4-specific rabbit IgG, confocal microscopy demon-
strated that the antigen to which NMO patients’ IgG binds
colocalizes with AQP4 in all of these tissues (Fig. 1 A).
 
NMO-IgG does not bind to CNS tissue from AQP4-null mice
 
Next, we investigated whether IgG in any of six coded pa-
tients’ sera bound to frozen sections of brain tissue obtained
from transgenic AQP4 null mice (11). Three were NMO-
IgG positive sera and three were control sera from patients
who had neuropsychiatric diagnoses (age- and sex-matched
to the NMO patients). IgG in the three NMO patients’ sera
bound to microvessels, pia, and subpia in the wild-type brain
tissue in a pattern that was indistinguishable from that
yielded by rabbit anti-AQP4–IgG (Fig. 1 B). However, nei-
ther human serum IgG nor the rabbit anti-AQP4–IgG
bound detectably to AQP4-null mouse brain tissue.
 
NMO-IgG binds selectively to membranes of 
AQP4-transfected cells
 
We tested the same six patients’ coded sera, in blinded con-
ditions, for IgG binding to a stably transfected human em-
bryonic kidney cell line (HEK-293) expressing a transgene
encoding full-length AQP4. No patient’s IgG bound to the
HEK-293 cells transfected with plasmid encoding GFP
without AQP4 (Fig. 2). However, IgG in the sera of all
three patients who had NMO stained the periphery of
AQP4-transfected cells intensely in a plasma membrane pat-
tern (corresponding to that seen with rabbit anti-AQP4–
Figure 1. Immunofluorescence reveals NMO-IgG colocalization 
with AQP4 in mouse tissues. (A) Brain: Virchow-Robin space (pial–astrocyte 
interface) at the junction of two folia in mouse cerebellar cortex and 
midbrain. NMO-antigen (green, fluorescein-conjugated anti-human IgG), 
AQP4 water channel protein (red, rhodamine-conjugated anti–rabbit IgG); 
merged images yellow. Kidney: colocalization of NMO and AQP4 antigens 
in distal collecting tubules of medulla. Stomach: basolateral membranes of 
epithelial cells in deep gastric mucosa. (B) WT mouse brain binds NMO-IgG 
(panel 1) in a pattern that is indistinguishable from its binding of AQP4-
specific IgG (panel 4); pia, subpia, and microvessels are stained. However, 
AQP4 knockout mouse brain (null) did not bind NMO-IgG (panel 2), and 
the serum of a control patient who had neuropsychiatric disease did not 
bind to WT brain (panel 3).
Figure 2. NMO-IgG binds selectively to AQP4-transfected cells. 
NMO-IgG (red, Alexa Fluor 594–conjugated anti–human IgG) binds to the 
plasma membrane of cultured human embryonic kidney (HEK-293) cells 
transfected with AQP4 (green, [GFP]-AQP4), but not to the plasma mem-
brane of control HEK-293 cells transfected with plasmid encoding GFP 
only. Nucleus is blue (stained with Hoescht). Overlap staining is yellow in 
the merged images. Note: GFP produced in control transfected cells is 
distributed throughout the nucleus and cytoplasm; GFP fused to AQP4 is 
membrane-bound. Cytoplasmic GFP-AQP4 (presumably in endoplasmic 
reticulum and transport packages) is not accessible to NMO-IgG in non-
permeabilized cells. Bars, 10 m.
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IgG), where it colocalized with GFP. The distribution of
GFP-AQP4 that did not colocalize with NMO-IgG was
compatible with endoplasmic reticulum or cytoplasmic
transport packages, presumably inaccessible to NMO-IgG in
nonpermeabilized cells. IgG in the three controls’ sera did
not bind to the GFP-AQP4–transfected cells.
 
NMO-IgG binds to the AQP4 water channel component of 
the dystroglycan complex
 
The selective binding of NMO-IgG to substrates expressing
AQP4, and its lack of reactivity with vector-transfected cells
and AQP4-null mouse brain, strongly implicate AQP4 as the
autoantigen of NMO-IgG. However, in astrocytic endfeet,
the distribution of AQP4 is dependent on its association
with elements of the dystroglycan complex at the BBB (12–
14). Therefore, it is conceivable that the target of NMO-
IgG is one of these associated proteins. To investigate this
possibility, we tested lysates of the AQP4 and control trans-
fected cell lines by immunoprecipitation. Despite endogenous
expression of 
 

 
-syntrophin, 
 

 
-dystroglycan, and dystrophin
(Dp71) in HEK-293 cells (Fig. 3 A), only GFP-AQP4 was
precipitated from lysates by serum IgG from patients who
had NMO (and by rabbit anti-AQP4–IgG; Fig. 3 B). The
immunoprecipitates did not contain 
 

 
-syntrophin, 
 

 
-dystro-
glycan, Dp71, or free GFP (Fig. 3 B). Control human IgG
did not precipitate GFP-AQP4 or any of the dystroglycan-
complex proteins.
Our results identify a water channel protein as the first
defined autoantigen pertinent to an inflammatory demyelin-
ating disorder of the human CNS. AQP4 is an integral pro-
tein of astrocytic plasma membranes (15–18), and is highly
concentrated in foot process domains facing microvessels
where it interacts with dystrophin-associated proteins (10,
17). The AQP4 channel is mercurial-insensitive, and is the
predominant water channel in the CNS. It has a pathophysi-
ologic role in brain edema formation following water intox-
ication (14, 19, 20) or focal cerebral ischemia (21). Brain
edema occurring in oncologic contexts is attributed to the
up-regulation of AQP4 in high-grade astrocytomas and in
reactive astrocytes related to cerebral adenocarcinoma me-
tastases (21, 22).
The present study is the first to implicate AQP4 in the
pathogenesis of any autoimmune disorder. NMO may repre-
sent the first example of a novel class of autoimmune chan-
nelopathies. Unlike MS, the cerebrospinal fluid in patients
who have NMO lacks evidence of intrathecal synthesis of
IgG, such as oligoclonal bands (4). IgG produced in periph-
eral lymphoid tissues has limited access to the extracapillary
space in the brain because of the endothelial tight junctions
that constitute the BBB. However, this barrier is not absolute
(23, 24). If AQP4-specific IgG is the proximal cause of
NMO, we envisage two potential mechanisms for the patho-
genicity of the small amount of IgG that penetrates this bar-
rier: (a) initiation of an inflammatory immune response
against astrocytic AQP4 protein by direct binding of antigen-
specific IgG molecules to the outer face of the water channel;
the homotetrameric structure of this protein would enable
potent activation of complement by appropriate IgG classes;
and (b) in the absence of initial complement activation, in-
flammation and demyelination may be a consequence of
IgG-mediated dysregulation of tissue water homeostasis. We
speculate that endothelial leakage accompanying inflamma-
tory events initiated by the binding of NMO-IgG to the ex-
tracellular face of AQP4 accounts for the abundance of IgM
in immune complexes deposited around penetrating vessels
in lesions of autopsied spinal cord from patients who had
NMO (2). Vascular leakage would allow secondary binding
of IgM rheumatoid factor (an extremely potent activator of
the complement cascade) to astrocytic endfeet displaying
NMO-IgG; low affinity interactions of other IgMs entering
the lesion site would amplify the inflammatory process
(Eisen, H.N., personal communication). Numerous autoan-
tibodies (nonorgan-specific and organ-specific) are a frequent
serologic finding in patients who have NMO (4). However,
unlike NMO-IgG, no other autoantibody is restricted to pa-
tients who have NMO. Lucchinetti et al. classified four MS
lesion subtypes immunohistochemically (25). The most
common (“pattern 2” MS lesion) is characterized by deposits
of complement and immunoglobulins. However, immune
complexes in “pattern 2” MS lesions are located at sites of
Figure 3. NMO-IgG immunoprecipitates GFP-AQP4 but not 
related dystroglycan complex proteins. (A) Lysates of HEK-293 cells 
transfected with GFP-AQP4 or GFP vector, and nontransfected cells 
were separated by SDS PAGE and probed with IgG’s specific for GFP, 
-syntrophin, -dystroglycan, or dystrophin (Dp71). Expression of 
-syntrophin, -dystroglycan, or dystrophin (Dp71) did not differ 
appreciably in any cell lysate. (B) Immune complexes were captured on 
protein G-agarose after incubating lysates of HEK-293 cells (stably trans-
fected with GFP-vector or GFP-AQP4) with pooled serum from patients who 
had NMO, pooled serum from control patients who had neuropsychiatric 
disease, or a rabbit AQP4-specific IgG. The complexes were analyzed by 
Western blot for GFP-AQP4 and for dystroglycan complex proteins 
(present in both lysates). NMO-IgG and AQP4-IgG captured GFP-AQP4. 
Control patients’ IgG did not capture GFP-AQP4. No IgG captured 
-syntrophin, -dystroglycan, or Dp71 (dystrophin). The cell lysate lane 
represents 1.5% of the total input used for immunoprecipitations. IgG 
from individual patients who had NMO yielded similar results.
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active myelin destruction and not in the prominent perivas-
cular distribution that characterizes NMO lesions.
The wide distribution of AQP4 does not explain the re-
stricted immunopathology of patients who have NMO. Re-
nal abnormalities have not been reported in NMO; however
AQP4-null mice have only minimal perturbation of renal
function, which reflects the small and noncritical nephron
segment that expresses AQP4 (11). Although NMO-IgG
binds to rodent brain tissues, inflammatory lesions in the
CNS of patients characteristically are restricted to optic
nerves and spinal cord. This incongruity may relate to po-
tential species differences in the distribution of AQP4 in the
CNS of humans and mice, or differences in accessibility of
AQP4 epitopes to IgG in vivo and in vitro
 
.
 
 Regional differ-
ences in the spatial distribution or molecular orientation of
AQP4 epitopes on astrocytic endfeet at sites other than optic
nerve and spinal cord might preclude complement activation
(26) or intermolecular cross-linking (27). Now that a puta-
tive target autoantigen has been identified for NMO, and
human IgG of high titer is available, direct investigation of
potential pathogenic autoimmune mechanisms is feasible in
laboratory animals by active immunization and by passive
transfer of selected patients’ autoantibodies (28, 29).
 
MATERIALS AND METHODS
 
These studies were approved by the Institutional Review Board of Mayo
Clinic, Rochester, Minnesota, and the Institutional Animal Care and Use
Committees of Mayo Clinic and the University of California, San Francisco.
 
Antibodies.
 
We selected sera from 13 adult patients (9 were pooled) in
whom NMO-IgG was detected at 1:3,840 dilution or greater by indirect
immunofluorescence on mouse CNS tissues (7), and from 3 healthy age-
matched subjects, 2 patients who had classical MS, 1 patient who had idio-
pathic myelopathy, and 3 patients who had miscellaneous neuropsychiatric
disorders. We pooled sera from 50 additional patients who had miscellaneous
disorders. Affinity-purified rabbit IgG specific for rat AQP4 (C-terminal res-
idues 249–323) was purchased from Sigma-Aldrich; normal rabbit serum was
obtained from a New Zealand white rabbit. Mouse monoclonal IgGs were
purchased from: Affinity BioReagents, Inc. (anti-
 

 
-syntrophin); Santa Cruz
Biotechnology, Inc. (anti-GFP); Novocastra Laboratories Ltd. (anti-
 

 
-dys-
troglycan); and Sigma-Aldrich (anti-dystrophin). Goat anti–human IgG (flu-
orescein-conjugated and rhodamine-conjugated) and rhodamine-conjugated
anti–rabbit IgG were purchased from Southern Biotechnology Associates,
Inc. Alexa Fluor 594–conjugated goat anti–human IgG was purchased from
Molecular Probes. Horseradish peroxidase conjugated anti–mouse IgG was
purchased from Southern Biotechnology Associates, Inc.
 
Fusion constructs and stable cell lines.
 
AQP4 was amplified from a
Quick Clone cDNA library (adult human cerebellum, BD Biosciences) and
cloned into pEGFP-C2 (CLONTECH Laboratories, Inc). HEK-293 cells
were stably transfected with pEGFP-C2 with and without AQP4 using Fu-
gene 6 transfection reagent according to the manufacturer’s protocol
(Roche). Stable cell lines were selected using 0.8 
 

 
g/ml geneticin (GIBCO
BRL). Expression of the GFP and GFP-AQP4 in the stable cell lines was
visualized in Western blot analyses using anti-GFP–IgG.
 
Cells and tissues.
 
We used three different substrates for immunostaining: (a)
frozen sections of adult mouse cerebellum, midbrain, liver, kidney, and stom-
ach; (b) frozen sections of cerebellum from adult transgenic AQP4-null mice
and wild-type control mice (11); and (c) human embryonic kidney (HEK-293)
cells transfected with plasmids encoding GFP-AQP4 or Vector-GFP.
 
Immunofluorescence.
 
Cells and tissues were fixed in 10% formalin for 4
min, washed in PBS, and blocked for 1 h in PBS containing 10% goat se-
rum. After incubation with primary antibodies for 40 min (tissues) or 1 h
(cell lines), the substrates were washed three times in PBS and incubated
with anti–human or anti–rabbit IgG for 30 min, washed in PBS, stained
with the DNA dye Hoescht at 1 
 

 
g/ml, and mounted in Prolong antifade
mounting media (Molecular Probes). Images were captured using a Zeiss
confocal microscope.
 
Immunoprecipitations and Western blot.
 
HEK-293 cells that were
stably transfected with pEGFP-C2 or GFP-AQP4 were lysed in buffer con-
taining: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, and 1% NP-40. Lysates
were clarified by centrifugation at 3700 rpm for 8 min to remove cellular de-
bris, and divided into three aliquots. A pool of high-titered sera from nine pa-
tients who had NMO (20 
 

 
L/ml), and subsequently from individual patients,
was added to one aliquot; pooled sera from 50 control patients was added to a
second aliquot; and rabbit anti-AQP4–IgG (Sigma-Aldrich) was added to a
third aliquot (2 
 

 
L/ml). Lysates were incubated with antibodies overnight at
4
 

 
C. Protein G-agarose (Zymed Laboratories) was added to each lysate (30
 

 
l/ml). After incubating for 1 h at 4
 

 
C, beads were pelleted and washed three
times in 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, and 0.1% NP-40. Beads
were resuspended in standard 2X SDS Laemmli sample buffer containing
 

 
-mercaptoethanol (20 
 

 
l/ml), to release immune complexes.
Subsequent steps were at room temperature. Immune complexes were
electrophoresed in 4–15% gradient polyacrylamide gels and transferred elec-
trophoretically to nitrocellulose paper. The nitrocellulose paper was
blocked in buffer (20 mM Tris, pH 7.6, 137 mM sodium chloride, 0.1%
Tween 20) containing 10% powdered milk, and exposed for 1 h to a panel
of IgG probes specific for: 
 

 
-syntrophin (1:1,000); GFP (1:1,000); 
 

 
-dys-
troglycan (1:100), and Dp71 dystrophin (1:1,000). Blots were washed three
times for 5 min in 20 mM Tris, pH 7.6, 137 mM sodium chloride, 0.1%
Tween-20 and then incubated for 30 min with horseradish peroxidase–
labeled goat anti–mouse IgG or goat anti–rabbit IgG. After washing, bound
IgG was detected autoradiographically by enhanced chemiluminescence
(GE Healthcare).
 
Transgenic AQP4 –/– mice. 
 
Transgenic AQP4-null mice were gener-
ated and characterized as described previously (11). These mice totally lack
AQP4 protein.
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